Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NATCO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NATCO PHARMA BIOCON /
NATCO PHARMA
 
P/E (TTM) x 35.5 34.8 101.8% View Chart
P/BV x 4.5 5.0 90.7% View Chart
Dividend Yield % 0.2 0.7 32.1%  

Financials

 BIOCON    NATCO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
NATCO PHARMA
Mar-19
BIOCON /
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs707849 83.3%   
Low Rs554557 99.4%   
Sales per share (Unadj.) Rs91.9573.8 16.0%  
Earnings per share (Unadj.) Rs16.7176.0 9.5%  
Cash flow per share (Unadj.) Rs24.2198.2 12.2%  
Dividends per share (Unadj.) Rs1.006.25 16.0%  
Dividend yield (eoy) %0.20.9 17.8%  
Book value per share (Unadj.) Rs101.6842.7 12.1%  
Shares outstanding (eoy) m600.0036.50 1,643.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.91.2 560.0%   
Avg P/E ratio x37.74.0 944.7%  
P/CF ratio (eoy) x26.13.5 735.4%  
Price / Book Value ratio x6.20.8 743.7%  
Dividend payout %6.03.6 168.5%   
Avg Mkt Cap Rs m378,33025,660 1,474.4%   
No. of employees `0006.15.0 123.7%   
Total wages/salary Rs m11,6533,559 327.4%   
Avg. sales/employee Rs Th8,994.34,225.3 212.9%   
Avg. wages/employee Rs Th1,900.7718.0 264.7%   
Avg. net profit/employee Rs Th1,635.31,295.9 126.2%   
INCOME DATA
Net Sales Rs m55,14420,945 263.3%  
Other income Rs m1,4441,302 110.9%   
Total revenues Rs m56,58822,247 254.4%   
Gross profit Rs m15,8837,948 199.8%  
Depreciation Rs m4,478810 552.8%   
Interest Rs m709193 367.4%   
Profit before tax Rs m12,1408,247 147.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,823 116.5%   
Profit after tax Rs m10,0266,424 156.1%  
Gross profit margin %28.837.9 75.9%  
Effective tax rate %17.522.1 79.1%   
Net profit margin %18.230.7 59.3%  
BALANCE SHEET DATA
Current assets Rs m48,22823,472 205.5%   
Current liabilities Rs m30,3767,287 416.9%   
Net working cap to sales %32.477.3 41.9%  
Current ratio x1.63.2 49.3%  
Inventory Days Days6892 74.1%  
Debtors Days Days8688 96.9%  
Net fixed assets Rs m64,13018,648 343.9%   
Share capital Rs m3,000365 821.9%   
"Free" reserves Rs m57,98034,525 167.9%   
Net worth Rs m60,98030,760 198.2%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92443,031 283.3%  
Interest coverage x18.143.7 41.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 92.9%   
Return on assets %8.815.4 57.3%  
Return on equity %16.420.9 78.7%  
Return on capital %16.827.4 61.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50611,536 134.4%   
Fx outflow Rs m10,3992,939 353.8%   
Net fx Rs m5,1078,597 59.4%   
CASH FLOW
From Operations Rs m11,5466,688 172.6%  
From Investments Rs m-7,138-6,122 116.6%  
From Financial Activity Rs m-2,417-509 474.9%  
Net Cashflow Rs m2,10366 3,186.4%  

Share Holding

Indian Promoters % 40.4 52.0 77.6%  
Foreign collaborators % 20.6 1.5 1,401.4%  
Indian inst/Mut Fund % 8.4 7.8 107.1%  
FIIs % 10.7 16.6 64.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.0 76.5%  
Shareholders   109,995 25,395 433.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 15, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS